overall survival

Overall Survival

Overview

Overall survival (OS) is a primary clinical endpoint used to measure the time from a defined starting point (such as diagnosis, treatment initiation, or randomization in a clinical trial) to death from any cause. In oncology and other serious medical conditions, OS represents one of the most clinically meaningful and objective measures of treatment efficacy, as it directly reflects patient lifespan rather than surrogate endpoints. OS is distinct from disease-specific metrics such as progression-free survival (PFS) and disease-free survival (DFS), which measure time to disease progression or recurrence, and is considered the gold standard endpoint in phase III randomized controlled trials. The robustness of OS as an outcome measure stems from its unambiguous definition and measurement—either a patient is alive or deceased at a given timepoint—making it less subject to interpretation bias than subjective clinical assessments. OS is frequently analyzed using statistical methods such as the Kaplan-Meier method to estimate survival curves and Cox proportional hazards models to calculate hazard ratios, which quantify the relative treatment effect between comparison groups.

Recent Publications Summary

Recent clinical studies across multiple cancer types have established OS as the critical efficacy measure in modern therapeutic trials. In soft-tissue sarcoma management, a 10-year analysis at a certified sarcoma centre investigated the impact of radiotherapy timing on local control and OS outcomes 42527052Jul. For extensive-stage small cell lung cancer, researchers developed a prognostic nomogram using real-world data to identify key clinical characteristics influencing OS in patients receiving serplulimab-based immunochemotherapy, integrating demographic and disease factors to predict individual patient survival 42533271Jul. In metastatic prostate cancer, a randomized trial examining PARP inhibition combined with androgen-signaling inhibition plus androgen deprivation therapy designated OS as a key secondary endpoint 42223064Jun. A phase 2 randomized trial in recurrent/metastatic head and neck squamous cell carcinoma established OS as the primary endpoint when comparing lenvatinib-pembrolizumab combination therapy against standard of care 42241967Jun. OS has also served as a critical secondary outcome in immunotherapy studies examining immune-related adverse events; research in mismatch repair-deficient and microsatellite instability-high digestive Cancers demonstrated correlations between severe immunotherapy-related adverse events and OS outcomes 42498483Jul. In elderly lung adenocarcinoma patients with brain metastases treated in the immunotherapy era, analyses specifically evaluated chemotherapy's effect on OS, examining whether conventional cytotoxic agents retain benefit 42481787Jul. Machine learning approaches, including deep hypergraph neural networks integrating clinical data and CT radiomics features, have been trained on progression-free survival and validated on OS prediction in non-small cell lung cancer to develop clinician-deployable prognostic tools 42008547Apr. Meta-analyses evaluating immune checkpoint inhibitors in metastatic castration-resistant prostate cancer designated OS and radiographic progression-free survival as primary outcomes, alongside objective response rate as a secondary measure 41672480Feb. In surgical oncology, robotic-assisted radical prostatectomy studies tracked OS alongside cancer-specific survival (CSS) and perioperative outcomes to comprehensively evaluate long-term oncologic benefit 42474561Jul. Across these diverse malignancies and treatment modalities, OS remains the definitive measure of therapeutic value, with confidence intervals and hazard ratios calculated to quantify treatment effects and establish clinical significance of new therapeutic approaches.

overall survival